We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CEMARGOS:BVCCementos Argos SA Analysis

Data as of 2026-06-11 - not real-time

COP 11,280.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

CEMARGOS is trading just above its short‑term support and roughly in line with its near‑term moving average, indicating a fragile price base. The relative strength index sits in the middle of its range, suggesting neither strong buying nor selling pressure. A bullish MACD histogram shows momentum edging higher despite the overall neutral trend. Recent earnings released showed an EPS shortfall while revenue modestly beat forecasts, which sparked a modest post‑market decline. Trading volume has been trending lower, hinting at waning short‑term participation. Volatility remains elevated, reflecting the cyclical nature of the building‑materials sector.
Valuation metrics place the stock well above its discounted cash‑flow estimate, signaling an overvalued condition. The forward price‑to‑earnings multiple has narrowed, yet the current price‑to‑earnings ratio remains high for the industry. A sizable dividend yield appears attractive, but a payout ratio well above earnings raises sustainability concerns. The company’s beta is modest, indicating limited sensitivity to broader market swings. Geographic exposure across Colombia, the Caribbean, Central America and the United States diversifies revenue but maintains exposure to emerging‑market dynamics and local regulatory shifts. Given the blend of technical resilience, valuation pressure and dividend risk, the stock warrants a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • recent EPS miss
  • decreasing volume
  • bullish MACD momentum

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • overvalued price relative to DCF
  • high dividend payout ratio
  • moderate beta and sector cyclicality

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • valuation gap persists
  • unsustainable dividend policy
  • exposure to emerging market regulatory risk

Key Metrics & Analysis

Financial Health

Revenue Growth-0.80%
Profit Margin9.23%
P/E Ratio27.9
ROE4.64%
ROA2.37%
Debt/Equity29.06
P/B Ratio1.4
Op. Cash FlowCOP568.6B
Free Cash FlowCOP-3957885501440

Technical Analysis

TrendNeutral
RSI47.9
SupportCOP 10,140.00
ResistanceCOP 12,200.00
MA 20COP 11,183.00
MA 50COP 11,644.40
MA 200COP 11,268.75
MACDBullish
VolumeDecreasing
Fear & Greed Index82.73

Valuation

Fair ValueCOP 4,662.01
Target PriceCOP 13,014.44
Upside/Downside15.38%
GradeOvervalued
TypeBlend
Dividend Yield3.86%

Risk Assessment

Beta0.56
Volatility44.90%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.